Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone propionate
Drug ID BADD_D00947
Description Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990[L5962].
Indications and Usage Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label]as well as inflammatory and pruritic dermatoses[F4355]. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis[L8309,F4358].
Marketing Status approved
ATC Code R03BA05; R01AD08; D07AC17
DrugBank ID DB00588
KEGG ID D01708
MeSH ID D000068298
PubChem ID 444036
TTD Drug ID D0LC6K
NDC Product Code 81522-002; 22552-0043; 51927-0013; 0113-0028; 41163-023; 0135-0582; 55910-607; 63868-656; 69842-765; 70000-0110; 72559-002; 46439-8729; 51552-1310; 11822-0901; 0113-0285; 37808-340; 41520-553; 0173-0601; 0173-0720; 50594-319; 53002-1294; 53002-7691; 59310-505; 59310-515; 0363-0652; 63629-8662; 63629-8663; 66993-078; 68788-7788; 0054-3270; 0713-0631; 80267-000; 81522-005; 16812-005; 64918-1600; 11673-262; 0173-0602; 0173-0718; 49035-063; 50090-0934; 53943-006; 55910-773; 60505-6205; 0363-0881; 63629-8658; 63629-8659; 64525-8000; 66993-079; 68196-208; 68788-8446; 68788-9678; 68998-600; 72189-004; 63654-380; 63981-001; 68196-210; 69842-757; 71143-375; 81522-073; 38779-2760; 53873-078; 55018-301; 11673-388; 46122-684; 49035-362; 50090-6053; 53002-1310; 53002-7693; 55301-506; 59310-114; 59310-311; 60505-0829; 63187-638; 63187-959; 63868-400; 64024-007; 68788-6926; 69306-016; 69842-900; 0536-1373; 49076-5501; 52482-001; 64918-1700; 11673-103; 11822-1177; 30142-258; 30142-301; 0113-7117; 36800-222; 0363-0024; 64525-6560; 69168-380; 70000-0613; 79903-071; 52221-106; 36800-572; 41163-100; 41250-634; 45802-222; 50090-2880; 50383-968; 59310-525; 62011-0269; 0363-1205; 63187-957; 68071-2582; 68071-4868; 68462-427; 0536-1183; 71205-443; 72288-119; 80425-0263; 53873-079; 63190-0520; 64918-1118; 37835-997; 0173-0719; 49348-182; 50090-0916; 50090-6058; 53002-2294; 60432-264; 63187-021; 63187-806; 0363-5012; 63629-8660; 63629-8661; 66993-080; 68016-723; 69842-770; 70518-1655; 0713-0632; 15308-0200; 58175-0361; 21130-089; 37808-205; 45802-221; 50090-6055; 50383-700; 56062-107; 59310-200; 60505-0955; 68391-133; 69256-061; 69842-228; 72288-333; 76162-656; 76420-106; 80159-201; 50909-5175; 63379-001; 11673-220; 21130-122; 36800-128; 41520-703; 46122-386; 51672-4095; 67296-1463; 53104-7531; 65089-0033; 0135-0576; 0168-0332; 0173-0600; 45802-441; 49035-200; 50090-0968; 51316-074; 60429-195
UNII O2GMZ0LF5W
Synonyms Fluticasone | Flonase | Flovent HFA | HFA, Flovent | Cutivate | Fluticasone Propionate | Propionate, Fluticasone | Flixonase | Flixotide | Flovent
Chemical Information
Molecular Formula C25H31F3O5S
CAS Registry Number 80474-14-2
SMILES CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Abnormal behaviour19.01.01.0010.000866%Not Available
Feeling of body temperature change08.01.09.012--Not Available
Ill-defined disorder08.01.03.0490.000590%Not Available
Polyp16.02.02.005; 08.01.06.010--Not Available
Adverse drug reaction08.06.01.009--Not Available
Disease recurrence08.01.03.0500.001345%Not Available
Obstructive airways disorder22.03.01.0110.000276%Not Available
Psychotic disorder19.03.01.002--
Sinus disorder22.04.06.002--
Chorioretinopathy06.09.01.0060.000276%Not Available
Skin abrasion23.03.11.018; 12.01.06.010--Not Available
Treatment failure08.06.01.0170.000719%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.0080.000405%Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.0040.001530%
Hypothalamic pituitary adrenal axis suppression05.03.04.0070.000184%Not Available
Candida infection11.03.03.021--
Respiratory symptom22.12.02.0130.000405%Not Available
Coeliac disease14.02.01.007; 10.04.04.012; 07.17.01.0080.000276%Not Available
Pancreatic mass07.18.02.007--Not Available
Negative thoughts19.15.02.012--Not Available
Arterial stenosis24.04.02.012--Not Available
Vagus nerve disorder17.04.06.004--
Asthmatic crisis22.03.01.0180.000276%Not Available
Glucocorticoid deficiency14.11.01.037; 05.01.02.0110.000184%Not Available
Central serous chorioretinopathy06.10.02.009--Not Available
The 11th Page    First    Pre   11 12    Next   Last    Total 12 Pages